Poll: Were you warned about side effects?

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic cancer.

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.

Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.